57596-02-8

Upstream product

• 108-30-5 succinic acid anhydride 
• 34678-64-3 1,2-bis(2-methylpropyloxy)benzene 
• 55403-98-0 1,2-diisopentoxybenzene 
• 5333-34-6 3-(3,4-dimethoxybenzoyl)propionic acid 
• 56872-60-7 ethyl 4-(3,4-dimethoxyphenyl)-4-oxobutanoate 

Downstream Products

• 145588-13-2 (E)-3-(3,4-dihydroxybenzylidene)-5-(3,4-dihydroxyphenyl)-2(3H)-furanone 
• 155787-75-0 (E)-4-(4-(3,4-diacetoxybenzylidene)-5-oxo-4,5-dihydrofuran-2-yl)-1,2-phenylene diacetate 
• 56872-61-8 ethyl 4-(3,4-dihydroxyphenyl)-4-oxobutanoate 
• 155787-74-9 5-(3,4-diacetoxyphenyl)-2(3H)-furanone 

Relevant academic research and scientific papers

Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559

Preparation and biological activity of the metabolites of the potent antihyperglycemic and antihyperlipidemic agent, (E)-4-{4-[(5-methyl-2-phenyl-1, 3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (TAK-559) (1), were investigated. Metabolites M

BE-23372M, a novel protein tyrosine kinase inhibitor. III. Synthesis

In a preceding paper, the physico-chemical properties and structural elucidation of BE-23372M, a potent novel protein tyrosine kinase inhibitor, were described. In this paper, we report the synthesis of BE-23372M from 3-(3,4-dimethoxybenzoyl)propionic aci